NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hopstem Biotechnology

Hopstem Biotechnology

Private
HangzhouHealthcare & Life Scienceshttp://hopstem.com/

Last Round

Series B

Oct 31, 2021

Total Funding Raised

$55.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Hopstem Biotechnology is a biotechnology company that develops induced pluripotent stem cell (iPSC)-derived therapies for central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Revenue Share

AI Layer

Non-AI

Keywords

induced pluripotent stem cellsiPSCschronic stroke treatmentallogeneic cell therapyneural cell therapyoff-the-shelf cell therapystem cell therapystroke recoveryregenerative medicinebrain repairneuroregenerationclinical-stage biotechnologyneurological disordersGMP manufacturingdrug discovery servicesneurotoxicity testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hopstem Biotechnology Comparables

Compare Hopstem Biotechnology with similar companies based on industry and business-model similarity.

Hopstem Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
XellSmart
81%
SanBio Company Limited
78%
Allife Medicine
75%

Hopstem Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 31, 2021
Series A ExtensionMay 28, 2021
Series A ExtensionDec 1, 2020
Series ADec 24, 2018

Key People

Founding team and executive leadership

D.Phil. Chia-Hua Maggie Ho

Chief Operating Officer

Executive Team

Hopstem Biotechnology Investors

Notable investors and investment history

Hopstem Biotechnology investors
InvestorRounds
Cybernaut Investment GroupAngel
Longmen CapitalSeries A Extension
Hillhouse InvestmentSeries B
YuanBio Venture CapitalSeries B, Angel, Series A Extension
Daoyuan CapitalSeries A
Empower InvestmentAngel
Lilly Asia VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 24, 2026

    Monthly visitors increased 61% MoM, reaching 1.4K.

  • Mar 25, 2025

    Monthly visitors grew 76% MoM, from 136 to 239.

Hopstem Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hopstem Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hopstem Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range8
Year Founded2017
Last FundingOct 31, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.